The short version of HGF mimetic fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-04-22. Anything still debated is marked as such rather than presented as settled.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
== Signs and symptoms == Often, every joint in a patient with arthrogryposis is affected; in 84% all limbs are involved, in 11% only the legs, and in 4% only the arms are involved. Every joint in the body, when affected, displays typical signs and symptoms: for example, the shoulder (internal rotation); wrist (volar and ulnar); hand (fingers in fixed flexion and thumb in palm); hip (flexed, abducted and externally rotated, frequently dislocated); elbow (extension and pronation) and foot clubfoot and less commonly congenital vertical talus. Range of motion can be different between joints because of the different deviations. Some types of arthrogryposis like amyoplasia have a symmetrical joint/limb involvement, with normal sensations. The contractures in the joints can result in delayed walking development in the first five years, but severity of contractures do not necessarily predict eventual walking ability or inability. Intelligence is normal to above normal in children with amyoplasia, but it is not known how many of these children have an above-normal intelligence, and there is no literature available about the cause of this syndrome. There are a few syndromes like the Freeman–Sheldon and Gordon syndrome, which have craniofacial involvement. The amyoplasia form of arthrogryposis is sometimes accompanied with a midline facial hemangioma. Arthrogryposis is not a diagnosis but a clinical finding, so this disease is often accompanied with other syndromes or diseases. These other diagnoses could affect any organ in a patient.
== History == It is commonly stated that the modern e-cigarette was patented in 2003 by Chinese pharmacist Hon Lik, but tobacco companies had been developing nicotine aerosol generation devices since as early as 1963.
==== Psychology ==== In psychology, in situ typically refers to studies conducted in a natural or real-world setting, as opposed to a controlled laboratory environment. This approach allows researchers to observe and measure psychological processes as they occur, increasing ecological validity—though often at the expense of experimental control over variables.
On 22 September 2014, VESA published the DisplayPort Alternate Mode on USB Type-C Connector Standard, a specification on how to send DisplayPort signals over the newly released USB-C connector. One, two or all four of the differential pairs that USB uses for the SuperSpeed bus can be configured dynamically to be used for DisplayPort lanes. In the first two cases, the connector still can carry a full SuperSpeed signal; in the latter case, at least a non-SuperSpeed signal is available. The DisplayPort AUX channel is also supported over the two sideband signals over the same connection; furthermore, USB Power Delivery according to the newly expanded USB-PD 2.0 specification is possible at the same time. This makes the Type-C connector a strict superset of the use cases envisioned for DockPort, SlimPort, and Mini and Micro DisplayPort. However, DisplayPort Dual-Mode (DP++) is not supported under USB-C alternate mode.
Sources: en.wikipedia.org
=== Tandem nursing === A mother can continue breastfeeding an older sibling while also breastfeeding a new baby; this is called tandem nursing. During the late stages of pregnancy, the milk changes to colostrum. While some children continue to breastfeed even with this change, others may wean. Most mothers can produce enough milk for tandem nursing, but the new baby should be nursed first for at least the first few days after delivery to ensure it receives enough colostrum. Breastfeeding triplets or larger broods is a challenge given babies' varying appetites. Breasts can respond to the demand and produce larger milk quantities; mothers have breastfed triplets successfully.
=== Perceptual symptoms === Unawareness or denial of severity of condition (anosognosia), which may prevent some from seeking recovery Perception of self as heavier or fatter than in reality, i.e., body image disturbance Altered body schema, i.e., a distorted and unconscious perception of one's body size and shape that influences how the individual experiences their body during physical activities. For example, a patient with anorexia nervosa may genuinely fear that they cannot fit through a narrow passageway. However, due to their malnourished state, their body is significantly smaller than someone with a normal BMI who would actually struggle to fit through the same space. In spite of having a small frame, the patient's altered body schema leads them to perceive their body as larger than it is.
1955: the Mexican League, previously independent, was classified as Double-A 1961: final season of the Southern Association 1963: the Eastern League and original South Atlantic League were moved from Class A to Double-A 1964: the original South Atlantic League was reconstituted as the Southern League 1967: the Mexican League moved to Triple-A Entering the 2020 minor league season (which was not played, due to the COVID-19 pandemic) the Texas League had been in Double-A since 1946, the Eastern League since 1963, and the Southern League since 1964. Prior to the 2021 season, Major League Baseball (MLB) reorganized the minor leagues. At that time, the existing leagues were temporarily renamed: Eastern League as Double-A Northeast, Southern League as Double-A South, and Texas League as Double-A Central. Following MLB's acquisition of the rights to the names of the historical minor leagues, MLB announced on March 16, 2022, that the leagues would revert to their prior names, effective with the 2022 season.
Sources: en.wikipedia.org
He served as President of the Kedah Tuberculosis Association, visiting Indian workers on rubber plantations to treat the disease, while she volunteered in the Kedah Family Planning Association. With the money from his medical practice, Mahathir indulged in his entrepreneurial streak and invested in property development, tin mining, a franchised petrol station, and a shop to do quick printing–sometimes to rescue Malay businessmen in trouble. He helped found the Malay Chamber of Commerce and served as its director.
=== Genetic stability === In order for there to be genetic stability within a marijuana strain the breeder has to go through selection and breeding, pinpointing the dominant and recessive genes within the two strains being crossed. After analyzing offspring with the preferred traits a breeder is looking for, the breeder will select the preferred traits and continue to breed those offspring to create the desired final product. Selection is a crucial process for a breeder to create a strain, especially if a client is looking for something with specific plant traits the breeder has to ensure that the hybrid's genetic traits have been closed in enough so unwanted traits aren't expressed in future harvests.
Muscle atrophy is the loss of skeletal muscle mass. It can be caused by immobility, aging, malnutrition, medications, or a wide range of injuries or diseases that impact the musculoskeletal or nervous system. Muscle atrophy leads to muscle weakness and causes disability. Disuse causes rapid muscle atrophy and often occurs during injury or illness that requires immobilization of a limb or bed rest. Depending on the duration of disuse and the health of the individual, this may be fully reversed with activity. Malnutrition first causes fat loss but may progress to muscle atrophy in prolonged starvation and can be reversed with nutritional therapy. In contrast, cachexia is a wasting syndrome caused by an underlying disease such as cancer that causes dramatic muscle atrophy and cannot be completely reversed with nutritional therapy. Sarcopenia is age-related muscle atrophy and can be slowed by exercise. Finally, diseases of the muscles such as muscular dystrophy or myopathies can cause atrophy, as well as damage to the nervous system such as in spinal cord injury or stroke. Thus, muscle atrophy is usually a finding (sign or symptom) in a disease rather than being a disease by itself. However, some syndromes of muscular atrophy are classified as disease spectrums or disease entities rather than as clinical syndromes alone, such as the various spinal muscular atrophies. Muscle atrophy results from an imbalance between protein synthesis and protein degradation, although the mechanisms are incompletely understood and are variable depending on the cause.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.